Recommended Global Diabetes & Endocrinology Webinars & Conferences
Asia Pacific & Middle East
Canada
DIABETIC COMPLICATIONS 2025
About Us
The 6th International Conference on Diabetic Complications is set to take place on November 24–25, 2025, in Barcelona, Spain, under the compelling theme “Bridging the Gap: From Prevention to Treatment in Diabetic Complications.” This prestigious two-day global event will bring together leading voices from across clinical, academic, and industry sectors to explore the latest advancements and challenges in diabetes and its related complications.
This conference serves as a collaborative platform for endocrinologists, diabetologists, internal medicine specialists, researchers, healthcare professionals, pharmacists, public health experts, industry representatives, academic scholars, and postgraduate students who are dedicated to understanding, preventing, and treating the complications that arise from diabetes.
Through keynote presentations, scientific sessions, case studies, and interactive panel discussions, participants will gain valuable insights into emerging technologies, treatment strategies, early diagnosis, and integrated care models for managing diabetes-related complications such as neuropathy, retinopathy, nephropathy, and cardiovascular issues.
Target Audience:
Endocrinologists & Diabetologists
Internal Medicine Specialists
Researchers & Academicians
Clinical Pharmacists & Industry Experts
Public Health Professionals
Diabetes Educators & Nurses
Nutritionists & Dietitians
Postgraduate Students
Abstract Submission Deadlines:
First Round: July 30, 2025
Second Round: September 30, 2025
Third Round: November 5, 2025
City Highlights:
Barcelona offers a stunning setting for this international gathering. Famous for its blend of art, architecture, and innovation, the city is home to Gaudí’s masterpieces like the Sagrada Família, vibrant marketplaces, Mediterranean beaches, and a rich culinary culture. With its historic charm and modern facilities, Barcelona creates the perfect backdrop for both academic excellence and cultural exploration.
Join us to share your expertise, connect with global peers, and contribute to the future of diabetic care.
CPD/CME/CEU credits
All registered participants of the 6th International Conference on Diabetic Complications, taking place on November 24-25, 2025 in Barcelona, Spain, will be eligible to receive 15–20 Continuing Education Credits (CME/CEU/CPD) for their full participation across both conference days.
These credits are globally recognized and awarded to reflect meaningful professional development in line with international accreditation standards.
CME (Continuing Medical Education) credits are particularly relevant for physicians, diabetologists, and medical specialists, helping them fulfill requirements for ongoing medical licensure and clinical practice.
CEU (Continuing Education Units) benefit nurses, clinical practitioners, and allied healthcare professionals as verifiable proof of continued academic engagement.
CPD (Continuing Professional Development) credits are accepted across a variety of disciplines, serving as evidence of knowledge acquisition and competency building in both academic and clinical settings.
Attending the conference not only enhances your knowledge of diabetic complications ranging from neuropathy and nephropathy to cardiovascular and ophthalmologic effects but also positions you to meet institutional mandates, contribute more effectively in multidisciplinary care settings, and stay compliant with global standards of excellence.
Participants will be issued an official certificate at the conclusion of the event that clearly states the number of CME/CEU/CPD credits earned. This certificate may be submitted to employers, academic institutions, or licensing authorities to verify your participation and professional advancement.
We invite you to join this impactful event in the beautiful city of Barcelona, where cutting-edge research meets cultural vibrance an ideal environment to grow your expertise and network with global leaders in diabetes care and chronic disease management.
Sessions
Diabetic retinopathy remains one of the most prevalent microvascular complications of diabetes and a leading cause of vision impairment globally. Prolonged hyperglycemia leads to damage in the retinal blood vessels, resulting in leakage, ischemia, and neovascularization. Early stages may be asymptomatic, which emphasizes the importance of routine ophthalmologic screening in diabetic patients. With advanced imaging modalities such as optical coherence tomography and fluorescein angiography, clinicians can detect subtle changes before irreversible damage occurs. Treatments such as anti-VEGF injections, laser photocoagulation, and vitrectomy have improved outcomes significantly. Current research is focused on identifying novel biomarkers for earlier diagnosis and exploring regenerative therapies to restore retinal integrity. Effective glycemic control, blood pressure management, and lipid regulation remain foundational in the prevention and progression of diabetic retinopathy.
Diabetic neuropathy is a debilitating consequence of chronic hyperglycemia, characterized by nerve damage that primarily affects the peripheral nerves. It presents in various forms, including peripheral, autonomic, proximal, and focal neuropathies. Patients often report symptoms such as numbness, burning pain, tingling, and muscle weakness, particularly in the lower extremities. The underlying pathophysiology involves metabolic and vascular factors leading to oxidative stress, inflammation, and impaired nerve repair mechanisms. Diagnosis is clinical, supported by nerve conduction studies and quantitative sensory testing. Current management strategies emphasize tight glycemic control, symptomatic relief with pharmacologic agents like duloxetine and pregabalin, and non-pharmacologic interventions such as physical therapy and neuromodulation. Emerging therapies targeting nerve regeneration and neuroprotection are under investigation, promising future advancements in patient care.
Diabetic nephropathy is a progressive kidney disease resulting from long-standing diabetes, marked by albuminuria, declining glomerular filtration rate, and eventual kidney failure. It is a leading cause of end-stage renal disease globally. Hyperglycemia-induced damage to glomerular capillaries leads to thickening of the basement membrane, mesangial expansion, and podocyte dysfunction. Diagnosis hinges on early detection of microalbuminuria and monitoring of renal function through serum creatinine and estimated GFR. Therapeutic strategies focus on strict glycemic and blood pressure control, use of renin-angiotensin-aldosterone system (RAAS) inhibitors, and sodium-glucose co-transporter-2 (SGLT2) inhibitors, which have shown renoprotective effects. Lifestyle modifications and dietary interventions also play critical roles. Recent advancements in biomarkers and precision medicine approaches are expected to enhance risk stratification and personalize treatment regimens.
Diabetic foot ulcers (DFUs) are a major complication of diabetes, resulting from a combination of peripheral neuropathy, peripheral arterial disease, and impaired wound healing. They represent a significant burden due to the risk of infection, lower limb amputation, and decreased quality of life. Effective management of DFUs requires a multidisciplinary approach, including offloading, wound debridement, infection control, and revascularization procedures when necessary. Early detection and patient education are vital in reducing incidence. Advanced wound care products, bioengineered skin substitutes, and negative pressure wound therapy are among the evolving treatment modalities. Integration of telemedicine and remote monitoring tools is also emerging as an innovative solution to improve DFU outcomes, particularly in underserved populations.
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with diabetes. Chronic hyperglycemia, insulin resistance, dyslipidemia, hypertension, and a pro-inflammatory state contribute to accelerated atherosclerosis. Diabetic patients are at increased risk for coronary artery disease, stroke, and peripheral vascular disease. Comprehensive risk assessment, including lipid profiles, blood pressure monitoring, and evaluation of renal function, is critical. Preventive strategies involve intensive glycemic control, statin therapy, ACE inhibitors, lifestyle modifications, and smoking cessation. Newer antidiabetic agents, such as GLP-1 receptor agonists and SGLT2 inhibitors, have demonstrated significant cardiovascular benefits beyond glucose lowering. Personalized medicine and advanced imaging techniques are expected to refine CVD risk prediction and management in diabetic populations.
Insulin resistance is a central pathogenic feature in type 2 diabetes, where the body's cells become less responsive to insulin, leading to hyperinsulinemia and impaired glucose uptake. It precedes the onset of diabetes and is closely associated with obesity, metabolic syndrome, and cardiovascular disease. Molecular mechanisms involve impaired insulin signaling pathways, lipid accumulation in muscle and liver, and chronic inflammation. Measurement techniques include HOMA-IR and euglycemic clamp studies. Management strategies emphasize weight reduction, increased physical activity, and dietary modifications. Pharmacologic options include metformin, thiazolidinediones, and emerging agents targeting insulin sensitization. Understanding genetic and epigenetic factors influencing insulin resistance is crucial for developing individualized therapies.
Beta cell dysfunction is fundamental to the pathogenesis of both type 1 and type 2 diabetes. In type 1 diabetes, autoimmune destruction of beta cells leads to absolute insulin deficiency. In type 2, a combination of insulin resistance and impaired beta cell function contributes to progressive hyperglycemia. Key factors include oxidative stress, lipotoxicity, glucotoxicity, and endoplasmic reticulum stress, which compromise beta cell survival and insulin secretion. Diagnostic markers such as C-peptide levels help assess residual beta cell function. Therapeutic approaches aim at preserving or restoring beta cell mass and function through immunomodulatory agents, incretin-based therapies, and regenerative medicine techniques, including stem cell therapy and islet transplantation.
Continuous glucose monitoring (CGM) represents a major advancement in diabetes management, providing real-time glucose readings and trends. It enables patients and healthcare providers to make informed decisions regarding insulin dosing, dietary intake, and physical activity. CGM systems consist of a sensor inserted under the skin, a transmitter, and a receiver or smartphone interface. Metrics such as time in range (TIR), glycemic variability, and glucose excursions offer comprehensive insights beyond traditional HbA1c measurements. CGM has been particularly beneficial in patients with type 1 diabetes and insulin-treated type 2 diabetes. Integration with insulin pumps and closed-loop systems has further improved glycemic outcomes. Ongoing innovations focus on enhancing sensor accuracy, longevity, and user comfort.
The artificial pancreas, also known as a closed-loop insulin delivery system, combines continuous glucose monitoring with automated insulin administration to mimic physiological glucose regulation. It represents a paradigm shift in diabetes care, significantly reducing hypoglycemic episodes and improving time in range. These systems utilize sophisticated algorithms to analyze glucose trends and deliver insulin via a pump, minimizing user intervention. Clinical trials have demonstrated substantial improvements in glycemic control and patient satisfaction. Regulatory approvals and real-world usage are expanding, with systems tailored for both adult and pediatric populations. Future developments aim at fully automated bihormonal systems incorporating glucagon delivery, ultimately approaching the functionality of a natural pancreas.
Glycemic variability has emerged as a critical dimension of diabetes management, representing fluctuations in blood glucose levels beyond average HbA1c values. These rapid swings between hyperglycemia and hypoglycemia are increasingly recognized as contributors to oxidative stress, endothelial dysfunction, and inflammatory responses that exacerbate both microvascular and macrovascular complications. Unlike sustained hyperglycemia, glycemic excursions are more closely associated with the risk of cardiovascular events, cognitive decline, and overall glycemic instability. Advances in continuous glucose monitoring (CGM) technology have enhanced the ability to detect, quantify, and respond to such fluctuations, allowing clinicians to personalize therapeutic strategies with greater precision. Managing glycemic variability involves a multifaceted approach including tailored pharmacotherapy, dietary interventions, and behavioral support. In clinical research, time-in-range (TIR) is becoming a complementary target alongside HbA1c, providing a more nuanced picture of glucose control. Addressing glycemic variability improves not only long-term outcomes but also daily quality of life for individuals with diabetes. A growing body of evidence supports its incorporation into routine care protocols, with regulatory agencies beginning to recognize its role in treatment assessments. Bridging the gap between research and clinical practice remains vital for integrating glycemic variability into holistic diabetes care models.
Hypoglycemia, a potentially life-threatening condition, remains a significant barrier in achieving optimal glycemic control, particularly in individuals undergoing intensive insulin therapy. Effective management requires both prevention and acute response strategies, emphasizing patient education and individualized care plans. Mild episodes may present with symptoms such as sweating, confusion, and dizziness, while severe hypoglycemia can lead to seizures, unconsciousness, and even death if not promptly addressed. Advances in insulin analogs, glucose-responsive technologies, and CGM systems have allowed for better detection and prevention of low blood glucose episodes. Patient-centric tools like hypoglycemia risk scores, real-time glucose alerts, and structured behavioral interventions enhance early recognition and mitigation. Clinical guidelines now stress the importance of minimizing hypoglycemia without compromising overall glycemic control. Collaborative care teams involving endocrinologists, educators, and caregivers play an integral role in improving adherence and reducing recurrent episodes. Moreover, newer therapies such as glucagon formulations for home use are expanding emergency treatment options. Hypoglycemia awareness and education should be a cornerstone of every diabetes management plan. Ongoing research into the psychosocial impacts of hypoglycemia continues to underscore the need for integrated care models, ensuring safer, more effective long-term outcomes in diabetes therapy.
Obesity and Type 2 Diabetes (T2D)
Obesity is one of the strongest modifiable risk factors for the development of type 2 diabetes (T2D), with excessive adiposity driving insulin resistance, metabolic dysfunction, and systemic inflammation. The intersection of these two chronic conditions presents a substantial clinical and public health challenge, requiring comprehensive strategies for prevention and treatment. Excess visceral fat leads to an overproduction of adipokines and free fatty acids, impairing insulin signaling and promoting hyperglycemia. Lifestyle interventions, including dietary modification and structured physical activity, remain the foundation of treatment, supported by behavioral counseling and continuous monitoring. Pharmacologic advancements such as GLP-1 receptor agonists and SGLT2 inhibitors not only improve glycemic control but also promote weight loss and cardiometabolic health. Bariatric surgery has also demonstrated long-term benefits in selected populations, often resulting in remission of diabetes. Obesity management should be individualized and culturally sensitive, addressing barriers to adherence and access to care. Given the rising prevalence of obesity worldwide, early intervention and integrated care models involving endocrinologists, nutritionists, and primary care physicians are essential. Reducing the burden of T2D through effective obesity management holds the potential to improve quality of life, reduce healthcare costs, and mitigate long-term complications associated with metabolic diseases.
The incidence of pediatric diabetes, particularly type 1 diabetes, has been rising globally, posing unique challenges in early diagnosis, management, and psychosocial support. In children and adolescents, effective diabetes care must be developmentally appropriate, family-centered, and technologically adaptive. Early-onset type 1 diabetes is associated with increased risks for long-term microvascular complications, making early and sustained glycemic control essential. Type 2 diabetes in youth, though less common, is also emerging due to the rising prevalence of childhood obesity and sedentary lifestyles. This form tends to progress more rapidly and respond poorly to traditional treatments compared to adult-onset T2D. Advances in insulin delivery systems, including insulin pumps and closed-loop artificial pancreas systems, offer promising outcomes for pediatric patients. Equally important are structured diabetes education programs involving families and schools to foster treatment adherence, psychological well-being, and resilience. Emotional health and transition to adult care services remain key aspects of comprehensive pediatric diabetes management. Multidisciplinary pediatric diabetes teams consisting of endocrinologists, dietitians, nurses, and psychologists are critical in delivering personalized, holistic care. Future research and healthcare policy must prioritize pediatric-specific strategies to mitigate lifelong complications and support optimal growth and development for children living with diabetes.
Diabetic ketoacidosis (DKA) is a severe acute complication of diabetes characterized by hyperglycemia, metabolic acidosis, and ketonemia. Often resulting from insulin omission, infection, or new-onset type 1 diabetes, DKA requires immediate medical intervention to prevent potentially fatal outcomes. Pathophysiologically, insulin deficiency leads to unchecked lipolysis and ketone production, resulting in metabolic acidosis and electrolyte imbalances. Clinical symptoms may include nausea, abdominal pain, rapid breathing, and altered mental status. Timely diagnosis, typically confirmed through blood glucose, ketone, and arterial pH measurements, is crucial. Standard management involves fluid replacement, intravenous insulin therapy, and correction of electrolyte imbalances, particularly potassium. With appropriate treatment, most patients recover without long-term consequences, though recurrent episodes can increase hospitalization rates and healthcare burden. Preventive strategies focus on patient education, early symptom recognition, and robust outpatient follow-up. Innovations in continuous glucose monitoring and telemedicine have enhanced the ability to detect early signs and reduce DKA incidence, especially in high-risk populations. For newly diagnosed individuals, structured education on insulin use, sick-day rules, and ketone testing plays a pivotal role in prevention. Continued emphasis on prevention and early intervention remains essential in reducing DKA-related morbidity and healthcare costs.
Pregnancy complicated by diabetes whether pregestational type 1 or type 2 diabetes or gestational diabetes mellitus (GDM) requires meticulous planning and monitoring to ensure maternal and fetal well-being. Hyperglycemia during pregnancy is associated with increased risks of congenital anomalies, preeclampsia, macrosomia, and perinatal complications. Early and tight glycemic control is crucial from preconception through delivery to minimize these risks. Management typically includes medical nutrition therapy, insulin therapy if necessary, and frequent glucose monitoring. Oral antidiabetic agents may be used selectively, though insulin remains the preferred treatment for many cases. Multidisciplinary care involving endocrinologists, obstetricians, dietitians, and diabetes educators is critical for achieving optimal outcomes. Regular fetal monitoring, assessment of maternal complications, and planning for delivery are integral components of care. Postpartum follow-up is essential, especially for women with GDM, who are at increased risk of developing type 2 diabetes later in life. Lifestyle modification and continued surveillance are recommended post-delivery to reduce long-term metabolic risks. Education and psychological support are equally important to empower women and reduce anxiety related to disease management during pregnancy. With structured care and vigilance, both maternal and neonatal outcomes can be significantly improved.
Microvascular complications of diabetes encompass retinopathy, nephropathy, and neuropathy each resulting from chronic hyperglycemia-induced damage to small blood vessels. These complications significantly impair quality of life and are major contributors to disability in people with long-standing diabetes. Retinopathy can lead to vision loss, nephropathy to end-stage renal disease, and neuropathy to chronic pain and limb amputations. The underlying pathogenesis involves advanced glycation end-products, oxidative stress, and chronic inflammation, all of which damage vascular endothelium and disrupt tissue perfusion. Early detection through routine screening, such as fundoscopic exams, urine microalbumin tests, and sensory assessments, is key to mitigating progression. Glycemic control, blood pressure management, and lipid regulation form the cornerstone of preventive and therapeutic strategies. Emerging therapies, such as anti-VEGF agents for retinopathy and SGLT2 inhibitors for nephropathy, offer new hope in slowing disease progression. Integrated care pathways that include multidisciplinary teams can enhance adherence and monitoring. Patient education about the signs and symptoms of microvascular damage is critical to ensuring timely intervention. Reducing the burden of these complications requires a proactive approach that emphasizes prevention, regular follow-up, and patient-centered care.
Macrovascular complications are a leading cause of morbidity and mortality in individuals with diabetes, primarily affecting the heart, brain, and peripheral arteries. Chronic hyperglycemia accelerates atherosclerosis through endothelial dysfunction, inflammation, and lipid abnormalities, significantly increasing the risk of cardiovascular diseases such as myocardial infarction, stroke, and peripheral artery disease. These complications often present earlier and progress more aggressively in diabetic populations. Hypertension, dyslipidemia, insulin resistance, and pro-thrombotic states further compound the cardiovascular burden. Management requires an integrated approach that includes tight glycemic control, aggressive blood pressure and lipid regulation, antiplatelet therapy, and lifestyle interventions. Novel therapies such as GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated significant cardiovascular benefits in patients with type 2 diabetes, redefining standards of care. Early identification through routine cardiovascular risk screening and the implementation of personalized treatment plans are essential. Preventing macrovascular complications not only improves life expectancy but also reduces the economic burden of diabetes-related hospitalizations and long-term care. Collaborative care models involving endocrinologists, cardiologists, and primary care providers play a pivotal role in comprehensive risk reduction and optimal disease management.
Inflammation plays a central role in the pathophysiology of both type 1 and type 2 diabetes. Chronic low-grade systemic inflammation contributes to insulin resistance, β-cell dysfunction, and the progression of diabetes-related complications. Adipose tissue, particularly visceral fat, acts as an active endocrine organ, secreting inflammatory cytokines such as TNF-α, IL-6, and CRP, which interfere with insulin signaling and glucose metabolism. In type 1 diabetes, autoimmunity-driven inflammation destroys pancreatic β-cells, while in type 2 diabetes, metabolic stress and inflammation perpetuate insulin resistance. Current research increasingly focuses on anti-inflammatory therapies as potential interventions in diabetes care. Agents such as IL-1 antagonists, salicylates, and statins have shown promise in reducing inflammatory markers and improving insulin sensitivity. Lifestyle modifications, including weight loss, exercise, and dietary interventions rich in antioxidants and anti-inflammatory nutrients, also significantly reduce systemic inflammation. Understanding the molecular mechanisms linking inflammation and metabolic dysfunction is vital for developing new therapeutic strategies. Recognizing and targeting inflammation offers a transformative perspective in diabetes treatment shifting the paradigm from glucose-centric to inflammation-modulating approaches for long-term disease control and complication prevention.
Individuals with diabetes are at increased risk for various infections due to immune system impairments, hyperglycemia-induced inhibition of neutrophil function, and poor circulation, especially in the lower extremities. Common infections include urinary tract infections, skin and soft tissue infections, pneumonia, and fungal infections such as candidiasis. Hyperglycemia creates a favorable environment for microbial growth and delays wound healing, increasing the severity and frequency of infections. Furthermore, diabetes increases susceptibility to rare but serious infections like malignant otitis externa and emphysematous pyelonephritis. Vaccination against influenza, pneumococcus, and hepatitis B is strongly recommended in diabetic populations. Early diagnosis, glycemic optimization, and timely antimicrobial therapy are critical to reducing infection-related complications. In hospital settings, infection control measures and patient education can significantly lower risks. The COVID-19 pandemic underscored the vulnerability of individuals with diabetes, as they experienced higher rates of hospitalization and mortality. As part of comprehensive diabetes care, infection prevention strategies should be integrated into routine follow-ups, emphasizing skin care, foot care, and regular screening for signs of infection. Strengthening patient immunity and metabolic control remains a cornerstone in mitigating infectious complications and improving clinical outcomes.
Lifestyle modification remains the foundation of both primary and secondary prevention strategies in diabetes management. Evidence consistently supports the role of physical activity, nutritional therapy, weight control, and behavioral interventions in preventing the onset of type 2 diabetes and mitigating complications in those already diagnosed. Exercise enhances insulin sensitivity, improves cardiovascular fitness, and supports weight loss, while a balanced diet rich in whole grains, vegetables, lean proteins, and healthy fats helps maintain glycemic stability and lipid control. Programs such as the Diabetes Prevention Program (DPP) have demonstrated that lifestyle interventions can reduce diabetes incidence by more than 50% in high-risk individuals. Behavioral counseling and psychological support are integral to sustaining lifestyle changes, especially given the chronic nature of the disease. In addition, smoking cessation, stress management, and sleep optimization contribute significantly to metabolic health. Personalized care plans that consider cultural, socioeconomic, and psychological factors ensure greater patient engagement and adherence. Prevention strategies should begin early, targeting at-risk populations through community health initiatives, digital tools, and policy reforms. Empowering individuals to make informed lifestyle choices not only improves health outcomes but also significantly reduces healthcare costs and the global burden of diabetes.
Market Analysis
The global market for diabetic complications continues to grow at a significant pace, driven by the rising prevalence of diabetes and the increasing awareness surrounding its long-term health impacts. As of recent global estimates, over 537 million adults are living with diabetes, a number expected to rise sharply by 2030. This surge directly correlates with a greater incidence of chronic complications such as diabetic neuropathy, nephropathy, retinopathy, and cardiovascular diseases. These complications impose a heavy burden on healthcare systems, generating immense demand for innovative diagnostics, therapeutics, and monitoring technologies. The increasing geriatric population and sedentary lifestyles further exacerbate the risk of complications, contributing to market expansion. Pharmaceutical companies, biotechnology firms, and medical device manufacturers are investing heavily in the research and development of novel solutions to address the complex pathways involved in diabetic complications. Advanced therapeutic approaches such as gene therapy, regenerative medicine, anti-inflammatory agents, and SGLT2 inhibitors are demonstrating significant promise in mitigating or delaying disease progression. Meanwhile, digital health technologies, including continuous glucose monitors, artificial pancreas systems, and telemedicine platforms, are revolutionizing chronic care management and real-time monitoring, opening new avenues for personalized care.
North America continues to lead the market due to its advanced healthcare infrastructure, strong reimbursement policies, and high awareness levels. However, the Asia-Pacific region is expected to witness the fastest growth over the coming years, fueled by a rapidly increasing diabetic population, improved access to healthcare services, and growing adoption of modern treatment options. Government initiatives and public-private partnerships across various countries are further enhancing research efforts and boosting market penetration in emerging economies. Barcelona, as the host city for the 6th International Conference on Diabetic Complications, offers a vibrant ecosystem for medical innovation and research collaboration. The region has seen substantial investment in biomedical sciences, attracting academic institutions, clinical researchers, and industry leaders focused on diabetes and related disorders. The conference will serve as a platform to explore market dynamics, showcase the latest advancements, and facilitate strategic discussions that can shape the future of diabetic care.
As healthcare providers continue to shift toward value-based care, there is a growing emphasis on early detection, prevention, and integrated care models. This trend is influencing market players to align their portfolios with holistic and long-term diabetes management solutions. With payer and patient expectations evolving, companies are focusing on real-world evidence, regulatory compliance, and outcomes-based research to sustain competitiveness. In this landscape, academic-industry collaborations, regulatory reforms, and patient-centric innovations will play a pivotal role in shaping the next phase of market evolution. The 6th International Conference on Diabetic Complications will gather thought leaders, clinicians, and industry experts to analyze these developments, exchange knowledge, and foster partnerships that drive forward the global effort in combating diabetic complications.
Past Conference Report
DIABETIC COMPLICATIONS 2022
The 5th International Conference on Diabetic Complications, held on July 20–21, 2022, in Bangkok, Thailand, was a remarkable success, bringing together clinicians, researchers, industry professionals, and healthcare practitioners from around the globe. The two-day event featured over 40 scientific presentations across plenary sessions, keynote lectures, and interactive panel discussions, addressing critical advancements and ongoing challenges in the management of diabetic complications.
Delegates from more than 25 countries participated, fostering a truly global exchange of knowledge and collaborative spirit. Key topics included diabetic retinopathy, neuropathy, nephropathy, cardiovascular risks, and innovative approaches in diabetes monitoring and treatment. Esteemed experts shared their insights on cutting-edge therapies, digital health integration, and precision medicine approaches to managing diabetes-related complications.
The conference also featured a strong poster session, with over 30 abstracts presented by young researchers and students, highlighting novel findings and fostering academic engagement. Attendees praised the event’s scientific quality, networking opportunities, and the hospitality of the host city. The organizing committee expressed sincere gratitude to all speakers, participants, and sponsors for their contributions to making the event a valuable platform for scientific advancement. The success of the 2022 conference has set a strong foundation for future meetings, including the upcoming 6th edition in Barcelona, Spain.
Past Reports Gallery
To Collaborate Scientific Professionals around the World
Conference Date November 24-25, 2025
For Sponsors & Exhibitors
Speaker Opportunity
Useful Links
Past Conference Report
Supported By
All accepted abstracts will be published in respective Conference Series International Journals.
Abstracts will be provided with Digital Object Identifier by